InnoCore participated in the DRIVE consortium to develop Diabetes-Reversing Implants for enhanced Viability and long-term Efficacy. Data published showed that the combination of SynBiosys®-based VEGF microspheres, exhibiting a continuous release of bioactive VEGF, and an islet encapsulation device encourages the formation of stable and mature blood vessels without exacerbating foreign body response.


For more information about the DRIVE consortium visit

For more information about the published data visit

Go back to news

We use cookies for analyzing visitors behavior.